Key Highlights
- Julie Clauss, MBA, appointed as Chief Operating Officer, bringing extensive biotech and pharmaceutical leadership experience.
- Christopher Butler, Ph.D., joins as Senior Vice President, Head of Chemistry, to steer strategic research and innovation.
- Odyssey focuses on pioneering precision immunomodulators and oncology medicines to address serious diseases.
Source: Business Wire
Notable Quotes
- “As we take extraordinary leaps to improve patient outcomes, we continue to recruit the best and brightest to join our team,” – Gary D. Glick, Ph.D., Founder and CEO at Odyssey Therapeutics
- “At Odyssey, I aim to leverage my leadership experience to help drive innovation, align functions and enhance operational efficiency to achieve meaningful, patient-centric solutions,” – Julie Clauss, MBA, COO at Odyssey Therapeutics
- “As expert drug hunters, they are at the forefront of scientific discovery, working to stay ahead of inflammatory diseases and cancer, and solve problems to get medicines to patients faster,” – Christopher Butler, Ph.D., SVP, Head of Chemistry at Odyssey Therapeutics
SoHC's Take
Odyssey Therapeutics, Inc. is strengthening its leadership cadre with the addition of Julie Clauss and Christopher Butler, marking a significant step in its mission to revolutionize the development of precision immunomodulators and oncology medicines. Clauss, with her profound leadership in driving business and research operations across major biotech and pharmaceutical companies, is poised to propel Odyssey towards operational excellence and achieving its ambitious vision. Butler, bringing a wealth of experience in synthetic and medicinal chemistry, is expected to lead the charge in fostering innovation and strategic direction in Odyssey’s chemistry department. This move underscores Odyssey’s commitment to advancing its pipeline and delivering transformative medicines, emphasizing the company’s position at the vanguard of scientific discovery and patient care in the battle against inflammatory diseases and cancer.